RANKINGS

Lowest P/E — Healthcare

Price-to-Earnings ratio. Lower P/E may indicate undervaluation relative to earnings.

80 companies with P/E Ratio data.

Ranked by P/E Ratio(80)

#	Ticker	Name	Industry	Market Cap	P/E Ratio
1	TRAW	Traws Pharma, Inc. TTM · 2025-09-30 Analysis WACC DCF	Pharmaceuticals	$6M	0.0
2	KYNB	KYNTRA BIO, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$25M	0.1
3	ORMP	ORAMED PHARMACEUTICALS INC. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$178M	2.8
4	RIGL	RIGEL PHARMACEUTICALS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$912M	2.8
5	ABEO	ABEONA THERAPEUTICS INC. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$280M	3.9
6	BTMD	biote Corp. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$33M	5.6
7	INVA	INNOVIVA, INC. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$1.5B	5.7
8	CF	CF INDUSTRIES HOLDINGS, INC. TTM · 2026-06-30 Analysis WACC DCF	Other	$17.3B	6.9
9	ACAD	ACADIA PHARMACEUTICALS INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$3.3B	8.8
10	REX	REX AMERICAN RESOURCES CORPORATION TTM · 2026-07-31 Analysis WACC DCF	Other	$1.4B	9.2
11	PLX	PROTALIX BIOTHERAPEUTICS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$224M	11.8
12	ZTS	Zoetis Inc. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$31.3B	11.9
13	NATR	NATURE’S SUNSHINE PRODUCTS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$224M	12.4
14	BMY	BRISTOL-MYERS SQUIBB COMPANY TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$117.6B	12.7
15	UG	UNITED-GUARDIAN, INC. TTM · 2026-06-30 Analysis WACC DCF	Other	$32M	12.9
16	NAGE	NIAGEN BIOSCIENCE, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$208M	13.0
17	FUL	FULLER H B CO TTM · 2026-08-29 Analysis WACC DCF	Other	$2.7B	13.4
18	CLX	CLOROX CO /DE/ TTM · 2026-03-31 Analysis WACC DCF	Other	$10.2B	13.5
19	FTLF	FITLIFE BRANDS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$87M	13.9
20	PPG	PPG INDUSTRIES INC TTM · 2026-03-31 Analysis WACC DCF	Other	$23.1B	14.5
21	LFVN	LIFEVANTAGE CORP FY · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$75M	14.8
22	JAZZ	Jazz Pharmaceuticals plc TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$14.1B	15.0
23	PAHC	Phibro Animal Health Corporation FY · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$1.5B	15.2
24	ANIP	ANI PHARMACEUTICALS, INC TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$1.7B	15.6
25	EMN	EASTMAN CHEMICAL CO TTM · 2026-06-30 Analysis WACC DCF	Other	$7.1B	16.1
26	CRON	CRONOS GROUP INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$1.2B	16.9
27	EXEL	Exelixis Inc TTM · 2026-07-03 Analysis WACC DCF	Pharmaceuticals	$14.8B	17.2
28	UTHR	United Therapeutics Corporation TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$23.6B	18.0
29	RPM	RPM International Inc. TTM · 2026-08-31 Analysis WACC DCF	Other	$12.4B	18.0
30	REGN	REGENERON PHARMACEUTICALS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$78.5B	18.1
31	TGTX	TG THERAPEUTICS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$8.5B	19.2
32	LXU	LSB Industries, Inc. TTM · 2026-06-30 Analysis WACC DCF	Other	$706M	19.2
33	CBT	Cabot Corporation TTM · 2026-06-30 Analysis WACC DCF	Other	$3.8B	20.2
34	IOSP	INNOSPEC INC. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$2.4B	20.2
35	NBIX	NEUROCRINE BIOSCIENCES, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$14.4B	20.4
36	KVUE	Kenvue Inc. TTM · 2026-06-28 Analysis WACC DCF	Other	$34.2B	20.7
37	ALTO	ALTO INGREDIENTS, INC. FY · 2025-12-31 Analysis WACC DCF	Other	$284M	21.3
38	IPAR	INTERPARFUMS, INC. TTM · 2026-06-30 Analysis WACC DCF	Other	$3.6B	21.4
39	PG	PROCTER & GAMBLE CO FY · 2026-06-30 Analysis WACC DCF	Other	$355.8B	22.2
40	JNJ	Johnson & Johnson FY · 2025-12-28 Analysis WACC DCF	Pharmaceuticals	$635.6B	23.7
41	LNTH	LANTHEUS HOLDINGS, INC. TTM · 2026-06-30 Analysis WACC DCF	Biotechnology	$6.5B	23.7
42	FTK	FLOTEK INDUSTRIES INC/CN TTM · 2026-06-30 Analysis WACC DCF	Other	$929M	24.5
43	BIIB	BIOGEN INC. TTM · 2026-03-31 Analysis WACC DCF	Pharmaceuticals	$33.9B	24.7
44	AMGN	Amgen Inc. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$225.8B	25.8
45	ABT	ABBOTT LABORATORIES TTM · 2026-03-31 Analysis WACC DCF	Pharmaceuticals	$176.2B	28.1
46	SCL	STEPAN COMPANY FY · 2025-12-31 Analysis WACC DCF	Other	$1.4B	29.5
47	NNNN	Anbio Biotechnology FY · 2025-12-31 Analysis WACC DCF	Biotechnology	$194M	30.2
48	HALO	HALOZYME THERAPEUTICS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$12.6B	30.5
49	WDFC	WD-40 COMPANY TTM · 2026-05-31 Analysis WACC DCF	Other	$2.7B	30.5
50	LIN	Linde plc TTM · 2026-06-30 Analysis WACC DCF	Other	$224.7B	31.0
51	LGND	LIGAND PHARMACEUTICALS INCORPORATED TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$6.2B	31.4
52	CHD	CHURCH & DWIGHT CO., INC. FY · 2025-12-31 Analysis WACC DCF	Other	$23.7B	32.2
53	VRTX	VERTEX PHARMACEUTICALS INC / MA FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$128.5B	32.5
54	BCPC	Balchem Corporation TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$5.4B	32.6
55	TEVA	TEVA PHARMACEUTICAL INDUSTRIES LIMITED FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$48.0B	34.1
56	SXT	Sensient Technologies Corp TTM · 2026-06-30 Analysis WACC DCF	Other	$5.5B	35.0
57	CL	COLGATE-PALMOLIVE COMPANY TTM · 2026-06-30 Analysis WACC DCF	Other	$71.7B	35.2
58	IDXX	IDEXX LABORATORIES INC /DE TTM · 2026-06-30 Analysis WACC DCF	Biotechnology	$41.3B	36.2
59	PFE	PFIZER INC TTM · 2026-06-28 Analysis WACC DCF	Pharmaceuticals	$161.9B	37.3
60	ALNY	ALNYLAM PHARMACEUTICALS, INC. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$30.4B	37.6
61	ECL	ECOLAB INC. TTM · 2026-06-30 Analysis WACC DCF	Other	$79.7B	37.7
62	SMG	Scotts Miracle-Gro Co TTM · 2026-06-27 Analysis WACC DCF	Other	$2.9B	39.3
63	SOLS	Solstice Advanced Materials Inc. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$9.6B	40.7
64	AVNT	AVIENT CORPORATION FY · 2025-12-31 Analysis WACC DCF	Other	$3.6B	43.6
65	LLY	ELI LILLY AND COMPANY FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$1.1T	51.1
66	ALB	ALBEMARLE CORPORATION TTM · 2026-06-30 Analysis WACC DCF	Other	$11.6B	51.9
67	HXL	Hexcel Corporation TTM · 2026-06-30 Analysis WACC DCF	Other	$6.4B	55.2
68	TECH	BIO-TECHNE Corp FY · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$11.4B	62.6
69	GYRE	Gyre Therapeutics, Inc. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$728M	73.7
70	LXFR	LUXFER HOLDINGS PLC TTM · 2026-03-29 Analysis WACC DCF	Other	$466M	80.3
71	IFF	INTERNATIONAL FLAVORS & FRAGRANCES INC TTM · 2026-06-30 Analysis WACC DCF	Other	$21.7B	81.5
72	MRK	Merck & Co., Inc. TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$358.9B	113.1
73	ABBV	AbbVie Inc. FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$496.8B	117.6
74	VCEL	VERICEL CORPORATION FY · 2025-12-31 Analysis WACC DCF	Pharmaceuticals	$2.1B	125.9
75	BMRN	BIOMARIN PHARMACEUTICAL INC TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$10.7B	146.9
76	EL	Estee Lauder Companies Inc FY · 2026-06-30 Analysis WACC DCF	Other	$36.2B	199.2
77	CORT	CORCEPT THERAPEUTICS INC TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$13.1B	237.4
78	ACB	AURORA CANNABIS INC FY · 2025-03-31 Analysis WACC DCF	Pharmaceuticals	$275M	241.3
79	RGEN	REPLIGEN CORP TTM · 2026-06-30 Analysis WACC DCF	Pharmaceuticals	$11.0B	263.7
80	DD	DUPONT DE NEMOURS, INC. TTM · 2026-06-30 Analysis WACC DCF	Other	$17.5B	317.6